Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210
Maniotis, 1999, Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry, Am J Pathol, 155, 739, 10.1016/S0002-9440(10)65173-5
Sharma, 2002, Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry, Prostate, 50, 189, 10.1002/pros.10048
Shirakawa, 2003, Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model, Breast Cancer Res, 5, 136, 10.1186/bcr585
Yue, 2005, Does vasculogenic mimicry exist in astrocytoma?, J Histochem Cytochem, 53, 997, 10.1369/jhc.4A6521.2005
Su, 2008, Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo, Int J Gynecol Cancer, 18, 476, 10.1111/j.1525-1438.2007.01034.x
Jiang, 2011, IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer, Oncogene, 30, 4498, 10.1038/onc.2011.154
Francescone, 2012, Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation, J Biol Chem, 287, 24821, 10.1074/jbc.M111.334540
Guzman, 2007, A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma, Arch Pathol Lab Med, 131, 1776, 10.5858/2007-131-1776-APSOVM
Sun, 2008, Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors, Hum Pathol, 39, 444, 10.1016/j.humpath.2007.07.018
Liu, 2011, Clinical significance of vasculogenic mimicry in human gliomas, J Neuro Oncol, 105, 173, 10.1007/s11060-011-0578-5
Johansen, 2006, Serum YKL-40, a new prognostic biomarker in cancer patients?, Cancer Epidemiol Biomarkers Prev, 15, 194, 10.1158/1055-9965.EPI-05-0011
Bernardi, 2003, YKL-40 as a marker of joint involvement in inflammatory bowel disease, Clin Chem, 49, 1685, 10.1373/49.10.1685
Johansen, 2005, Increased serum YKL-40 in patients with pulmonary sarcoidosis-a potential marker of disease activity?, Respir Med, 99, 396, 10.1016/j.rmed.2004.09.016
Nordenbaek, 2005, High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement, Scand J Rheumatol, 34, 293, 10.1080/03009740510018598
Lebensztejn, 2007, Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B, Adv Med Sci, 52, 120
Dehn, 2003, Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer, Acta Obstet Gynecol Scand, 82, 287, 10.1034/j.1600-0412.2003.00010.x
Dupont, 2004, Early detection and prognosis of ovarian cancer using serum YKL-40, J Clin Oncol, 22, 3330, 10.1200/JCO.2004.09.112
Jensen, 2003, High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer, Clin Cancer Res, 9, 4423
Johansen, 2004, High serum YKL-40 level in patients with small cell lung cancer is related to early death, Lung Cancer, 46, 333, 10.1016/j.lungcan.2004.05.010
Mitsuhashi, 2009, Serum YKL-40 as a marker for cervical adenocarcinoma, Ann Oncol, 20, 71, 10.1093/annonc/mdn552
Ngernyuang, 2014, Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer, Int J Biochem Cell Biol, 51, 45, 10.1016/j.biocel.2014.03.021
Qi, 2015, Wnt3a promotes the vasculogenic mimicry formation of colon cancer via Wnt/β-catenin signaling, Int J Mol Sci, 16, 18564, 10.3390/ijms160818564
Landoni, 1997, Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer, Lancet, 350, 535, 10.1016/S0140-6736(97)02250-2
Quinn, 2006, Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer, Int J Gynaecol Obstet, 95, S43, 10.1016/S0020-7292(06)60030-1
Ana, 2016, Bevacizumab in the treatment of cervical cancer – current evidence and next steps, Eur Oncol Haematol, 12, 32, 10.17925/EOH.2016.12.01.32
Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027
Colombo, 2012, Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, vii27, 10.1093/annonc/mds268
Monk, 2009, Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study, J Clin Oncol, 27, 4649, 10.1200/JCO.2009.21.8909
Yu, 2015, Advancements in recurrent and metastatic cervical cancer, Am J Hematol Oncol, 11, 26
Tewari, 2014, Improved survival with bevacizumab in advanced cervical cancer, N Engl J Med, 370, 734, 10.1056/NEJMoa1309748
van der Schaft, 2004, Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells, J Natl Cancer Inst, 96, 1473, 10.1093/jnci/djh267
Dunleavey, 2012, Vascular mimicry: concepts and implications for anti-angiogenic therapy, Curr Angiogenes, 1, 133, 10.2174/2211552811201020133
Steeg, 2003, Angiogenesis inhibitors: motivators of metastasis?, Nat Med, 9, 822, 10.1038/nm0703-822
Shao, 2015, Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization, Oncotarget, 6, 40507, 10.18632/oncotarget.5943
Sun, 2006, Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma, Oncol Rep, 4, 693